Committed to advancing global healthcare through pioneering molecular research, high-yield active pharmaceutical ingredients, and precision therapeutic formulations.
Partner With UsDeveloping targeted small-molecule inhibitors and next-generation delivery platforms.
Formulations designed to manage hypertension, dyslipidemia, and vascular health.
Accessible biological equivalents targeted at chronic autoimmune and inflammatory disorders.
Innovative therapies crossing the blood-brain barrier to treat neurodegenerative conditions.
At Lumos Pharmaceutical Pvt. Ltd., our focus is on closing the gap between complex molecular discovery and direct patient accessibility. Operating under strict cGMP and ISO-certified protocols, our state-of-the-art manufacturing facilities leverage modern synthetic chemistry and formulation analytics to provide stable, efficacious healthcare interventions.
"Precision molecular synthesis is not merely an engineering feat; it is a healthcare imperative."
Leads Lumos's global drug discovery programs, bringing over 22 years of analytical biochemistry and patent commercialization experience.
"Sustainable scale requires aligning uncompromised compliance with responsive supply-chain logistics."
Directs corporate governance, regulatory market access, and international pharmaceutical trade partnerships across emerging markets.
| Product Code | Generic Name / Molecule | Dosage & Route | Therapeutic Indication |
|---|---|---|---|
| LMS-011 | Lumocitinib Phosphate | 10 mg Oral Tablet | Targeted Kinase Inhibition |
| LMS-042 | Atorvastatin Calcium Trihydrate | 20 mg / 40 mg Film-Coated | Cardiovascular / Lipid Control |
| LMS-089 | Metformin Hydrochloride (ER) | 500 mg Extended Release | Type 2 Diabetes Mellitus |
| LMS-104 | Pregabalin Extended Formulation | 75 mg Hard Gelatin | Neuropathic Pain Management |
Corporate Headquarters
Lumos Pharmaceutical Pvt. Ltd.
Plot 48, Biotech & Pharma Corridor,
Industrial Development Area, Phase II
Email: partner@lumospharma.com
Direct Line: +1 (800) 555-0199
Regulatory Desk: regulatory@lumospharma.com